RxHub announces network expansion
ST. PAUL, Minn. RxHub has announced an expansion to its RxHub National Patient Health Information Network, which now provides clinicians information for more than 200 million patient records at the point of care.
“RxHub provided significant education for payers on the importance of providing prescription benefit and history information to clinicians at the point of prescribing in 2007,” stated Tom Groom, senior vice president of business development for RxHub. “Payers of prescription claims realize that the benefits of connecting to RxHub can improve patient safety and clinical workflow efficiency which results in measurable cost savings in healthcare delivery.”
A study conducted by the Gorman Group in 2007 found that approximately 70 percent of the safety and savings advantages of ePrescribing resulted from doctors being given immediate access to patient level medication histories, safety alerts, and preferred drug options before prescriptions are electronically transmitted to pharmacies.
“ePrescribing transactions processed by RxHub increased by 38 percent from 2006,” stated JP Little, chief operating officer for RxHub. “While this rate of growth is impressive, RxHub is positioned to make a monumental impact to the ePrescribing industry in 2008.”
Taro settles patent suit, launches generic Trileptal
HAWTHORNE Taro announced Wednesday that it has settled a patent lawsuit with Novartis and will launch oxcarbazepine tablets, the generic version of Novartis’ Trileptal. Oxcarbazepine tablets are indicated to treat seizures.
The litigation with Novartis centered on Taro’s Paragraph IV certification challenging Novartis’ patent protection on Trileptal. On Nov. 15, 2007, Taro received Food and Drug Administration approval for its abbreviated new drug application for oxcarbazepine tablets in 150 mg, 300 mg and 600 mg strengths, but the company waited to launch the drug until the lawsuit was settled.
According to Taro, Trileptal currently has annual U.S. sales of approximately $700 million.
Sciele to launch six medications in 2008
ATLANTA In addition to Sciele’s announcement last week, reported in Drug Store News, that it will launch its new Sular formulation during the first quarter of 2008, the company also announced plans to launch five other drugs this year:
- two new dosages of fenofibrate for the treatment of mixed dyslipidemia
- Prandin for Type 2 diabetes
- PrandiMet for Type 2 diabetes (pending FDA approval)
- a head lice asphyxiation product (pending FDA approval)
- a women’s health product
Sciele reaffirmed its full-year guidance at the JPMorgan 26th Annual Health Care Conference yesterday. As previously announced, full-year 2007 revenue is expected to range between $375 million and $385 million. The company expects full-year 2008 revenues to range from $440 million to $455 million.